GlassScriptPhysician profile
Renee Trang Pham
NPI 1003526187
$1,745.35
in general payments reported to CMS, 2019-2025
24 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $150 · 2024: $522 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $351.86 | 2023-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $173.74 | 2023-2025 | Jardiance, Mounjaro |
| Radius Health, INC. | $158.18 | 2024-2025 | Tymlos |
| Embecta Corp. | $126.87 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Amgen INC. | $116.28 | 2024-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $110.88 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.12 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $74.16 | 2025 | |
| Insulet Corporation | $58.13 | 2025 | Omnipod |
| Tandem Diabetes Care, INC. | $56.95 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $56.69 | 2025 | Korlym |
| Kyowa Kirin, INC. | $49.64 | 2025 | |
| Xeris Pharmaceuticals, INC. | $47.10 | 2025 | Recorlev |
| Exact Sciences Corporation | $46.33 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $38.79 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27.38 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $24.96 | 2025 | Imcivree |
| Madrigal Pharmaceuticals | $23.41 | 2025 | Rezdiffra |
| Dexcom, INC. | $21.02 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $21.01 | 2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $18.89 | 2025 | Capvaxive, Gardasil 9 |
| Alvogen INC | $17.13 | 2024 | Teriparatide |
| Antares Pharma, INC. | $16.94 | 2024 | Xyosted |
| Tolmar, INC. | $15.89 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.